Define Optimal 2nd Line Treatment and Sequence: Biomarker

Gabriel Malouf, MD, PhD of Pitié-Salpêtrière Hospital Defines Optimal 2nd Line Treatment and Sequence: Biomarker at the 12th European International Kidney Cancer Symposium 2017